Opendata, web and dolomites

IL7RsignaTHER SIGNED

Antibody-based IL-7R targeted therapies

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IL7RsignaTHER project word cloud

Explore the words cloud of the IL7RsignaTHER project. It provides you a very rough idea of what is the project "IL7RsignaTHER" about.

grant    arthritis    severe    melanoma    il    minimize    40    hematological    unmet    free    adults    market    lymphoid    autoimmune    rheumatoid    generate    peripheral    ectopic    breast    bowel    multiple    scenario    surface    consolidator    led    intensive    strategies    therapies    aggressive    broad    detrimental    regimens    children    diseases    therapeutic    mediated    chemotherapy    worse    plays    sclerosis    remarkable    prognosis    lymphocytic    inflammatory    conventional    frequent    indications    648455    lymphoblastic    7r    commercialize    hodgkin    chronic    bladder    leukemic    outcome    pediatric    monoclonal    cell    complications    colorectal    malignancies    treatment    childhood    relapses    disease    dismal    pathological    biopharmaceuticals    cells    signaling    obvious    extends    risk    improvement    80    remission    il7signeture    antibody    lymphoma    axis    leukemia    cancers    explore    expression    alive    lung    solid    acute    malignancy    innovative    data    glioblastoma    preliminary    efficient    erc    diabetes    adjusted    cancer    cog    agent    dependence    considerably   

Project "IL7RsignaTHER" data sheet

The following table provides information about the project.

Coordinator
INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES 

Organization address
address: AVENIDA PROF EGAS MONIZ
city: LISBOA
postcode: 1649 028
website: www.imm.ul.pt

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Total cost 0 €
 EC max contribution 150˙000 € (0%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2019-PoC
 Funding Scheme ERC-POC-LS
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2021-06-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INSTITUTO DE MEDICINA MOLECULAR JOAO LOBO ANTUNES PT (LISBOA) coordinator 150˙000.00

Map

 Project objective

Acute lymphoblastic leukemia (ALL), a highly aggressive hematological cancer, is the most frequent childhood malignancy and the second most common acute leukemia in adults. The use of risk-adjusted multi-agent intensive chemotherapy has led to a remarkable improvement in treatment outcome of pediatric cases, with more than 80% of children with ALL being alive and disease-free at 5 years. However, a significant number of relapses still occur, whose prognosis is dismal, and the intensive regimens used are often associated with long-term, severe complications. In adults, the scenario is considerably worse: only 30–40% of the cases achieve long-term remission. Therefore, there is an obvious unmet need, and a major challenge, to develop novel, more efficient therapeutic strategies that specifically target the leukemic cells, minimize the detrimental side effects associated with conventional therapies and improve overall treatment outcome. Based on exciting and robust preliminary data from our ERC Consolidator Grant IL7sigNETure (CoG-648455), we now propose to explore the dependence of ALL cells on IL-7/IL-7R-mediated signaling and the broad expression of IL-7R on the surface of ALL cells to develop and commercialize novel monoclonal antibody-based biopharmaceuticals that we will generate targeting the IL-7/IL-7R axis for treatment of this malignancy. Our innovative therapeutic strategies have significant market potential that extends beyond ALL. Other possible indications include other lymphoid malignancies (Hodgkin's lymphoma, peripheral T-cell lymphoma, chronic lymphocytic leukemia), solid cancers with ectopic expression of IL-7R (including melanoma, breast, lung, bladder and colorectal cancer, or glioblastoma), and autoimmune and chronic inflammatory diseases (diabetes, multiple sclerosis, rheumatoid arthritis, inflammatory bowel disease) in which the IL-7/IL-7R axis plays a pathological role.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IL7RSIGNATHER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IL7RSIGNATHER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

evolSingleCellGRN (2019)

Constraint, Adaptation, and Heterogeneity: Genomic and single-cell approaches to understanding the evolution of developmental gene regulatory networks

Read More  

IMMUNOTHROMBOSIS (2019)

Cross-talk between platelets and immunity - implications for host homeostasis and defense

Read More  

HEIST (2020)

High-temperature Electrochemical Impedance Spectroscopy Transmission electron microscopy on energy materials

Read More